We found that registry data regarding receipt of radiation therapy (RT) for breast cancer are highly variable and depend on patient factors and the population-based registry charged with collecting these data. Studies
Introduction
The Institute of Medicine has long advocated the development of systems to measure and monitor the quality of cancer care received by the US population (1) . Such systems could identify populations who receive poor-quality care, thereby enabling targeted interventions to improve care and outcomes. Population-based tumor registries represent one important avenue for measuring quality of cancer care. For example, in breast cancer, data from the Surveillance, Epidemiology, and End Results (SEER) population-based registry program have been used to determine whether radiation therapy (RT) is used appropriately after lumpectomy and mastectomy (2) (3) (4) (5) (6) . Such studies have largely concluded that RT is underutilized in breast cancer patients and, alarmingly, that underutilization has actually worsened in recent years (3) .
Inherent to the use of registry data is the assumption that receipt of RT is correctly ascertained by the reporting registry. Several prior studies have generally suggested good accuracy of RT ascertainment by SEER registries when compared against the gold standard of Medicare billing claims (7, 8) . However, such studies focused on the 9 to 13 SEER registries available at that time and did not evaluate the accuracy of RT coding in the expanded SEER program, which now includes 16 registries with linked Medicare billing claims, or in other population-based registries that do not participate in SEER. As registry data continue to be used by investigators to evaluate RT utilization and outcomes, a contemporary evaluation of the accuracy of RT coding is warranted.
Accordingly, we sought to evaluate the accuracy of registry RT ascertainment against the gold standard of Medicare billing claims in a contemporary cohort of breast cancer patients. To accomplish this, we used linked SEEReMedicare data, representing approximately 26% of the US population, to (1) determine underascertainment, sensitivity, specificity, and k for registry RT receipt, and (2) identify factors associated with underascertainment of RT. In addition, we partnered with the three largest non-SEER registriesdFlorida, New York, and Texas, representing an additional 20% of the United Statesdto compare RT ascertainment among these registries to the SEER registries.
Methods and Materials

Data sources
The SEER Program of the National Cancer Institute assembles information on cancer incidence and survival from 16 populationbased tumor registries, with a case ascertainment ratio of 97% (9) . Data collected include patient demographics, tumor characteristics, and treatment, including RT receipt, during the initial treatment course. The National Cancer Institute has linked SEER records to the medical billing claims of Medicare beneficiaries. Medicare covers inpatient and outpatient medical care for approximately 95% of the US population aged 65 years and older (10) .
Distinct from the SEEReMedicare data, the Florida, New York, and Texas Cancer Registries have also linked their records to Medicare billing claims under the guidance of the National Cancer Institute, the Association of Schools of Public Health, and the National Program of Cancer Registries at the Centers for Disease Control and Prevention, with support from their respective state departments of health. Data elements captured by these registries are similar in structure and format to the data collected by the SEER registries.
Description of study cohorts
From the SEEReMedicare data, we identified 127,308 women aged 66 years or older with a diagnosis of invasive breast cancer during the period 2001-2007. Patients were excluded if they had noncontinuous Medicare Part A and B or health maintenance organization coverage within 12 months before and after diagnosis, were diagnosed from autopsy or death certificate, presented with metastatic disease or unknown stage at diagnosis, or were diagnosed with a second cancer or died within 1 year of diagnosis, leaving 73,077 patients for the analytic cohort (Supplementary Table e1 , available online) (11) .
A similar approach was used to create analytic cohorts for the FloridaeMedicare (nZ17,165), New YorkeMedicare (nZ5,292), and TexaseMedicare cohorts (nZ15,403), with the exception that the New York cohort only included patients diagnosed in [2004] [2005] [2006] (Supplementary Table e1 ).
Receipt of radiation
Radiation therapy receipt was determined from both registry data and Medicare claims. Registry data were considered to indicate RT receipt if patients were coded as receiving "Beam radiation," "Combination of beam with implants or isotopes," or "Radiation, NOSdmethod or source not specified" during the initial treatment course. Medicare claims were considered to indicate RT receipt if at least 1 claim for delivery of RT was present within 1 year of diagnosis (Supplementary Table e2 ). The period of 1 year was chosen because this was the timeframe established by the Commission on Cancer of the American College of Surgeons (ACoS) as a quality measure for receipt of RT after breastconserving surgery (BCS). Receipt of brachytherapy, a newer form of breast cancer RT, was not considered in our definition of RT receipt because it was not a standard-of-care procedure during 2001-2007, and we were thus concerned that it might not be coded accurately by registries. The RT start interval was defined as time in days from the diagnosis date to the first Medicare claim for delivery of RT. Because SEER reports only month and year of diagnosis, each patient was assigned a diagnosis date at the midpoint of the month of diagnosis. For patients whose RT started before the assigned diagnosis date (nZ19), the RT start interval was reclassified as zero.
Key covariates
Race, age, and residence at the time of diagnosis were determined from registry data. "Urban" was defined as big metropolitan, metropolitan, or urban, and "rural" was defined as less urban or rural using SEER definitions. Type of breast surgery Abbreviations: BCS Z breast-conserving surgery; NA Z not available; SEER Z Surveillance, Epidemiology and End Results registry. * The original SEER-9 registries include Atlanta, Connecticut, Detroit, Hawaii, Iowa, New Mexico, San FranciscoeOakland, SeattleePuget Sound, and Utah. The SEER-other registries include those added in 1992 and later (San Jose, Los Angeles, Rural Georgia, Greater California, Kentucky, Louisiana, and New Jersey).
y Cell sizes have been rounded to protect the confidentiality of the unknown group in accordance with our data user's agreement.
was determined by selecting the most extensive surgery reported by either registry data or Medicare billing claims within 12 months of diagnosis (Supplementary Table e2 ). The SEER registries were grouped as the original SEER-9 registries (Atlanta, Connecticut, Detroit, Hawaii, Iowa, New Mexico, San FranciscoeOakland, SeattleePuget Sound, and Utah) versus the newer SEER registries (San Jose, Los Angeles, Rural Georgia, Greater California, Kentucky, Louisiana, and New Jersey). * Specificity, PPV, NPV, and Cohen's k statistic were calculated for radiation therapy (RT) receipt coded by registries compared with the gold standard of Medicare billing claims. Underascertainment of RT receipt was defined as the number of cases in which Medicare claims indicated that the patient received RT but registry data indicated that the patient did not receive RT, divided by the total number of cases in which Medicare claims indicated that the patient received RT (1 -sensitivity).
Statistical analysis
y The original SEER-9 registries include Atlanta, Connecticut, Detroit, Hawaii, Iowa, New Mexico, San FranciscoeOakland, SeattleePuget Sound, and Utah. The SEER-other registries include those added in 1992 and later (San Jose, Los Angeles, Rural Georgia, Greater California, Kentucky, Louisiana, and New Jersey).
claims. We defined underascertainment (1 -sensitivity) as the number of cases in which Medicare claims indicated that the patient received RT but registry data indicated that the patient did not receive RT, divided by the total number of cases in which Medicare claims indicated that the patient received RT. Univariate predictors of RT receipt were tested using the Pearson c 2 test for categoric variables.
For our second objective, we used the SEEReMedicare cohort to evaluate factors associated with underascertainment of RT. To accomplish this, we first determined underascertainment for each 10-day increment in RT start interval. Ordinary least-squares regression estimated the association between underascertainment and RT start interval among the entire cohort and also among only those with stage I disease. We then used multivariate logistic regression to identify factors associated with RT underascertainment. Candidate covariates were included on the basis of clinical significance or univariate P<.25. The model was iteratively refined to minimize colinearity. Goodness of fit was assessed using the method of Hosmer and Lemeshow (12) .
For our third objective, underascertainment, sensitivity, specificity, positive predictive value, negative predictive value, and k were calculated for the Florida, New York, and Texas cancer registries. Unadjusted logistic regression compared underascertainment for these three registries with the SEER registries. (Adjusted analyses could not be conducted because our existing data user's agreements prohibit data sharing across institutions.)
This study was granted exempt status by the institutional review board of the University of Texas M.D. Anderson Cancer Center.
An a of 0.05 was used for all analyses. All statistical tests were two-sided.
Results
Descriptive characteristics of SEEReMedicare cohort
Of 73,077 patients identified in the SEEReMedicare cohort, median age at diagnosis was 75 years, 56.9% (nZ41,581) underwent BCS, 37.8% (nZ27,657) underwent mastectomy, and 18.0% (nZ13,123) received chemotherapy ( Table 2 ). The SEER-9 registries had an underascertainment of 14.1% (95% CI 13.9-14.2%), compared with 21.8% (95% CI 21.7-22.0%) for the newer SEER registries (P<.001). Sensitivity/underascertainment did not change with year of diagnosis (PZ.43).
Predictors of underascertainment in SEEReMedicare cohort
Delay in the start of RT was associated with an increase in underascertainment (0.12% per day, 95% CI 0.11-0.13% per day; R 2 Z0.94) (Fig. 1 ). This increase persisted even when analyzing only patients with stage I disease (nZ25,400, 0.12% per day, 95% CI 0.10-0.13% per day; R 2 Z0.88). In adjusted analysis, factors associated with underascertainment included residence in a newer SEER registry (odds ratio [OR] 1.70, 95% CI 1.60-1.80; P<.001) or rural county (OR 1.34, 95% CI 1.21-1.48; P<.001) and delay in start of RT (OR 1.006 per day, 95% CI 1.006-1.007 per day; P<.001) ( Table 3) . Advanced age and treatment with mastectomy were also associated with higher likelihood of underascertainment, but year of diagnosis and race were not.
Comparison of Florida, New York, and Texas registries with the SEER registries
Sensitivity of RT reporting was 48.4% for Florida, 56.1% for Texas, and 81.1% for New York, compared with a range of 72.6-94.4% for the SEER registries (Table 4 ). Underascertainment Fig. 1 . Underascertainment of radiation therapy by interval from diagnosis to start of radiation therapy. Underascertainment was determined for each 10-day increment in days from the diagnosis date to the first claim for delivery of RT. Ordinary least-squares regression estimated the association between underascertainment and RT start interval. Vertical bars represent 95% confidence intervals.
was 51.6% for Florida, 43.9% for Texas, and 18.9% for New York, compared with a range of 5.6-27.4% for the SEER registries ( Figure 2 
Discussion
In this unique cohort of breast cancer patients representing nearly half the US population, we found significant variation in the ascertainment of RT by cancer registries. Whereas some registries demonstrated extremely high sensitivity, exceeding 90%, sensitivity for other registries was below 60%. Further, we found that the original SEER-9 registries had the most accurate data, while two non-SEER registries had the least accurate data. In addition, we found that rural residence and increased RT start interval negatively impacted ascertainment of RT receipt by tumor registries. These results illustrate that in certain settings RT can be coded with good accuracy but that caution is generally needed when evaluating studies of RT utilization that rely on registry data alone.
For example, influential studies reported in The Lancet and Journal of Clinical Oncology used tumor registry data to argue that the likelihood of inappropriate localeregional management of (nZ36,047) . The modeled outcome is underascertainment of RT, defined as the number of cases in which Medicare claims indicated that the patient received RT but registry data indicated that the patient did not receive RT, divided by the total number of cases in which Medicare claims indicated that the patient received RT. In this model, an OR >1 indicates a higher of odds of underascertainment.
y Statistically significant. z The original SEER-9 registries include Atlanta, Connecticut, Detroit, Hawaii, Iowa, New Mexico, San FranciscoeOakland, SeattleePuget Sound, and Utah. The SEER-other registries include those added in 1992 and later (San Jose, Los Angeles, Rural Georgia, Greater California, Kentucky, Louisiana, and New Jersey). Abbreviations: BCS Z breast-conserving surgery; CI Z confidence interval; NPV Z negative predictive value; PPV Z positive predictive value; SEER Z Surveillance, Epidemiology and End Results. Names of SEER registries are suppressed in according with our data user's agreement to protect confidentiality of individual SEER registries. Values are percentages. * Specificity, PPV, NPV, and Cohen's k statistic were calculated for radiation therapy (RT) receipt coded by registries compared with the gold standard of Medicare billing claims. Underascertainment of RT receipt was defined as the number of cases in which Medicare claims indicated that the patient received RT but registry data indicated that the patient did not receive RT, divided by the total number of cases in which Medicare claims indicated that the patient received RT (1 -sensitivity). breast cancer has increased over time, as BCS gained acceptance in breast cancer management (2, 3) . These studies defined appropriate management as total mastectomy with axillary lymph node dissection or BCS with axillary lymph node evaluation and RT. However, because these studies used registry data alone, it is likely that underascertainment of RT by registries resulted in inappropriately low rates of suitable localeregional management reported by these studies. Similarly, our findings call into question other studies of SEER registries alone, which reported underuse (4, 13) , rural disparities (6), and geographic variation (3, 5, 14) in RT receipt for breast cancer.
Prior literature has evaluated ascertainment of RT by tumor registries in comparison with Medicare claims. In a cohort of women diagnosed in 1992-1993, Du et al (8) evaluated accuracy of the SEER-9 registries and reported underascertainment of 18.7%. In a similar study evaluating women diagnosed in 1991-1996, Virnig et al (7) reported underascertainment of only 13.5%. In our study underascertainment was 14.1% for the original SEER-9 registries, compared with 21.8% for the newer SEER registries, suggesting that underascertainment remains a persistent issue, particularly with the newer registries.
Various studies have also evaluated ascertainment of RT by registries in comparison with medical record review or patient self-report (15, 16) . For example, a comparison of data from the California Cancer Registry with medical record review found that underascertainment was 25.6% from 1992 to 1996 (17) . In addition, a survey of 2290 breast cancer patients residing in the catchment areas for the Los Angeles or Detroit registries found that underascertainment was 32.0% in Los Angeles and 11.3% in Detroit (18) . In this study, underascertainment was significantly associated with registry, income, mastectomy receipt, chemotherapy receipt, and diagnosis at a hospital not accredited by the ACoS. Our study complements and expands on this prior literature by revealing that efforts to improve RT ascertainment should focus on newer registries, delayed radiation treatment, and rural regions.
Several underlying factors likely account for the measured variation in ascertainment of RT by tumor registries. For example, registries have various policies in place regarding how they obtain information regarding receipt of RT. These policies are most often dependent on registry funding and staffing. Some registries actively survey facilities that deliver RT to ascertain treatment, whereas other registries must passively wait for reporting from treating facilities (18) . Because certified tumor registrars typically work within ACoS-accredited hospitals, it is also conceivable that regional variation in the proportion of patients treated at none ACoS-accredited hospitals or freestanding centers may also impact RT ascertainment. As highlighted in our analysis, registries with a more rural population may have more variation in ascertainment of RT, which could explain some of the difference between the Florida/Texas and the New York registries.
Various strategies could be used to improve RT coding by tumor registries. For example, passage of the Health Information Technology for Economic and Clinical Health Act establishes automated incident case reporting using electronic medical records as the new standard for cancer registries (19) . Compliance will be linked to the Medicare and Medicaid Electronic Health Record incentive program. Allowing registries to further access treatment information from electronic medical records or associated claims for cancer treatment could substantially improve RT ascertainment in a cost-effective manner.
Recently, the National Radiation Oncology Registry (NROR) has been created through collaboration between the Radiation Oncology Institute and the American Society for Radiation Oncology. The purpose is "To address the need for accurate, comprehensive, and clinically rich data, to determine national patterns of care, outcomes, and gaps in treatment quality, and to compare the effectiveness of different treatment modalities" (20) . If the NROR could develop strategic data sharing agreements with local tumor registries, the information flowing into the NROR could then be used by registries to improve accuracy of RT ascertainment. Such arrangements would be in the best interest of patients and the field of radiation oncology, because the data provided would help to identify patient populations who remain at risk for inappropriate omission of RT and allow interventions to improve access to RT for such patients.
There are certain limitations of this analysis to consider. For example, we used receipt of RT according to Medicare claims data as the gold standard because our primary aim was to identify factors that contributed to underasceratainment of RT by tumor registries. Nevertheless, reliance on Medicare claims alone may also result in underascertainment of RT receipt, for example in patients who receive RT in military or Veterans Affairs Hospitals and thus do not generate Medicare billing claims. However, in our analysis, only 1.4% of patients were coded as receiving RT by SEER registries but not by Medicare claims, suggesting that this is a relatively uncommon event. In addition, it is possible that Medicare claims may inappropriately classify patients as receiving RT when such RT was not delivered as part of the initial treatment course. To mitigate this possibility, we excluded patients with distant disease who have the highest risk for early recurrence, which would require RT, and those with second cancers diagnosed within 1 year of the index diagnosis, who may require RT for another indication. Nevertheless, it remains possible that Medicare claims could misclassify a small percentage of patients as having received RT when such treatment was not part of the initial treatment course. Such misclassification would bias results by decreasing the measured sensitivity of SEER registries. However, in our analysis, the association between RT delay and underascertainment persisted even when analyzing only patients with stage I disease, who have the lowest risk of disease recurrence requiring RT outside the first treatment course.
In summary, population-based tumor registries, although critical to oncologic research, are highly variable in ascertainment of RT receipt and should generally be augmented with other data sources when evaluating quality of breast cancer care. Future work should identify opportunities to use electronic medical records and resources from the radiation oncology community to improve accuracy of registry treatment data.
